Health

Results: 7885-7896 of 9389

PR Newswire associated0

Lancet Digital Health Publishes Study Confirming MAGENTIQ-COLO™ AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data

ACCESSWIRE associated0

OmniGuide(TM) Holdings and UROTECH (Medi-Globe Group Subsidiary) Announce Partnership to Expand Global Urology Patient Therapies

Launch of New Features, discover the unique Incision Location Optimization tool on SAV-IOL Toric Calculator. (Image SAV-IOL SA)

New Swiss Made Features for Cataract Surgery Lens Selection

Music Licensing, Inc. (OTC: SONG) Secures Intellectual Property Rights for Listerine "Mouthwash" Antiseptic

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer

Business Wire logo

Caldera Medical's Humanitarian Effort Reaches New Heights: 400,000 Women Treated Worldwide

Business Wire logo

An Invitation to Innovaderm’s 5th Breakfast Event, This Year’s Focus is on Alopecia Areata (AA)

PR Newswire associated0

AtomVie Global Radiopharma Collaborates with RLS & UPPI to Strengthen its Existing U.S. Radiotherapeutic Distribution Network

Business Wire logo

ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases